Boule Diagnostics

Interim report
Q1 2023

Financial Highlights

NET SALES, MSEK
143.1
GROSS MARGIN
46.2
%
OPERATING PROFIT, MSEK
12.1
OPERATIONAL CASH FLOW, MSEK
-9
DSC5200A (1)

Continued improvement in performance

Sales and order intake increased in March and we delivered continued improvement in performance. I am particularly pleased that the gross margin for the Group continues to improve and that the efficiency improvements initiated at the beginning of the year are resulting in an improved gross profit.

Our extended cooperation agreement with FujiFilm in Europe is promising and boosts our potential in the veterinary segment. In the second quarter, we will launch a new veterinary product.  

CEO COMMENTS

Net sales by region

Net sales by product

Near-patient diagnostics

Complete Blood Count (CBC) is the most common test for in vitro diagnostics. The decentralized and patient-related hematology segment has an estimated market value of just over SEK 8 billion, while the corresponding segment for the veterinary market is valued at approximately SEK 2.6 billion

Map En

200
+

Distributors in 100 countries

SEK
8
BILLION

Addressable market Human

150
MILLION

Tests per year

TO THE REPORT

ABOUT BOULE DIAGNOSTICS

Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies.